These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 8644334)

  • 1. Follow-up of patients with borderline changes in renal allograft biopsies: clinical outcome and evaluation of other histological features in addition to tubulitis.
    Papadimitriou J; Drachenberg C; Anderson L; Bartlett S; Johnson L; Klassen D; Hoehn-Saric E; Weir M; Schweitzer E
    Transplant Proc; 1996 Feb; 28(1):517-8. PubMed ID: 8644334
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of subclinical rejection on renal allograft histology and function at 6 months.
    Rush D; Jeffery J; Trpkov K; Solez K; Gough J
    Transplant Proc; 1996 Feb; 28(1):494-5. PubMed ID: 8644325
    [No Abstract]   [Full Text] [Related]  

  • 3. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group.
    Woodle ES; Thistlethwaite JR; Gordon JH
    Transplant Proc; 1996 Dec; 28(6):3163-4. PubMed ID: 8962225
    [No Abstract]   [Full Text] [Related]  

  • 4. Intraoperative renal biopsy and its relation to renal function at the end of the first year posttransplantation.
    Vazquez MC; Schiavelli RO; Sabbatiello R; Castiglioni T; Pattin M
    Transplant Proc; 1996 Feb; 28(1):372-3. PubMed ID: 8644271
    [No Abstract]   [Full Text] [Related]  

  • 5. Can a diagnosis of renal allograft rejection be based on histology alone?
    Midtvedt K; Hartmann A; Sund S
    Clin Transplant; 1998 Aug; 12(4):300-2. PubMed ID: 9686323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protocol biopsies in stable renal transplant patients under triple immunosuppression: results at 6 months.
    Rush DN; Jeffery JR; Gough J
    Transplant Proc; 1994 Oct; 26(5):2576. PubMed ID: 7940797
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of 214 percutaneous renal allograft biopsies.
    Kim HC; Park SB; Lee SH; Cho WH; Park CH; Park KK
    Transplant Proc; 1994 Aug; 26(4):1997-8. PubMed ID: 8066648
    [No Abstract]   [Full Text] [Related]  

  • 9. Proteinuria after renal allograft: assessment based on severity and causes.
    Jeong HJ; Kim YS; Oh CK; Park K; Choi IJ
    Transplant Proc; 1994 Aug; 26(4):2132-3. PubMed ID: 8066695
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the Banff criteria for the histological diagnosis of rejection in renal allograft biopsies.
    Dooper MM; Hoitsma AJ; Koene RA; Bogman MJ
    Transplant Proc; 1995 Feb; 27(1):1005-6. PubMed ID: 7878778
    [No Abstract]   [Full Text] [Related]  

  • 11. Risks and benefits of graft biopsy in renal transplantation under cyclosporin-A.
    Kiss D; Landmann J; Mihatsch M; Huser B; Brunner FP; Thiel G
    Clin Nephrol; 1992 Sep; 38(3):132-4. PubMed ID: 1395164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do we have to treat subclinical rejections in early protocol renal allograft biopsies?
    Masin-Spasovska J; Spasovski G; Dzikova S; Petrusevska G; Lekovski Lj; Ivanovski N; Popov Z
    Transplant Proc; 2007 Oct; 39(8):2550-3. PubMed ID: 17954170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol core biopsy as intermediate efficacy end-point in chronic kidney allograft rejection.
    Yilmaz S; Taskinen E; Häyry P; Isoniemi H
    Transplant Proc; 1996 Feb; 28(1):491-3. PubMed ID: 8644324
    [No Abstract]   [Full Text] [Related]  

  • 14. Protocol biopsies in kidney transplant recipients: histologic findings as prognostic markers for graft function and outcome.
    Masin-Spasovska J; Spasovski G; Dzikova S; Grcevska L; Petrusevska G; Lekovski Lj; Popov Z; Ivanovski N
    Transplant Proc; 2005 Mar; 37(2):705-8. PubMed ID: 15848508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of immunocytochemistry (LCA and LEU-7) in diagnosis of renal allograft rejection.
    Gibson IW; Marcussen N; Brown RW; Solez K; Truong LD
    Transplant Proc; 1996 Feb; 28(1):457-64. PubMed ID: 8644313
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of Banff borderline acute rejection among renal allograft recipients.
    Matoza JR; Danguilan RA; Chicano S
    Transplant Proc; 2008 Sep; 40(7):2303-6. PubMed ID: 18790219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure.
    Waid T;
    Clin Transplant; 2005 Oct; 19(5):573-80. PubMed ID: 16146546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The detrimental effect of early rejection on long-term renal allograft outcome.
    Sumrani N; Delaney V; Daskalakis P; Hong JH; Cacciarelli TV; Sommer BG
    Transplant Proc; 1992 Oct; 24(5):1750-2. PubMed ID: 1412824
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation between the Banff 97 classification of renal allograft biopsies and clinical outcome.
    Tanaka T; Kyo M; Kokado Y; Takahara S; Hatori M; Suzuki K; Hasumi M; Toki K; Ichimaru N; Yazawa K; Hanafusa T; Namba Y; Oka K; Moriyama T; Imai E; Okuyama A; Yamanaka H
    Transpl Int; 2004 Feb; 17(2):59-64. PubMed ID: 14551678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival.
    Hariharan S; Alexander JW; Schroeder TJ; First MR
    Clin Transplant; 1996 Dec; 10(6 Pt 1):538-41. PubMed ID: 8996775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.